Literature DB >> 22139897

Exercise capacity and muscle strength in patients with cirrhosis.

Jacqueline C Jones1, Jeff S Coombes, Graeme A Macdonald.   

Abstract

Exercise capacity and muscle strength are predictors of outcome in a number of clinical populations. Advanced liver disease is a catabolic state, and patients often have muscle wasting. However, the relationships between exercise capacity, strength, and outcomes for patients undergoing liver transplantation are poorly understood. Thirteen studies have examined the association between these parameters in patients with cirrhosis, and they have found a significant reduction in the exercise capacity and muscle strength of patients with cirrhosis versus healthy controls. These impairments appear to be independent of the etiology of cirrhosis, but the data are equivocal with respect to their association with disease severity. Two studies reported a significant and independent association between pretransplant exercise capacity and posttransplant survival. Another 2 studies found that exercise training was well tolerated in patients with cirrhosis and resulted in improvements in exercise capacity (both studies) and muscle mass (1 study). These data are provocative and suggest that measuring and improving the exercise capacity and muscle strength of patients with cirrhosis who are awaiting liver transplantation could potentially improve outcomes.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22139897     DOI: 10.1002/lt.22472

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  42 in total

1.  Exercise manual for liver disease patients.

Authors:  Vivian Limongi; Daniele Costa Dos Santos; Aurea Maria de Oliveira da Silva; Ilka de Fátima Santana Ferreira Boin; Raquel Silveira Bello Stucchi
Journal:  World J Transplant       Date:  2016-06-24

Review 2.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

Review 3.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

Review 4.  Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases.

Authors:  Rita Rastogi Kalyani; Mark Corriere; Luigi Ferrucci
Journal:  Lancet Diabetes Endocrinol       Date:  2014-03-06       Impact factor: 32.069

5.  Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.

Authors:  Soichi Iritani; Kenji Imai; Koji Takai; Tatsunori Hanai; Takayasu Ideta; Tsuneyuki Miyazaki; Atsushi Suetsugu; Makoto Shiraki; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Gastroenterol       Date:  2014-05-10       Impact factor: 7.527

6.  Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization.

Authors:  Michael A Dunn; Deborah A Josbeno; Amit D Tevar; Vikrant Rachakonda; Swaytha R Ganesh; Amy R Schmotzer; Elizabeth A Kallenborn; Jaideep Behari; Douglas P Landsittel; Andrea F DiMartini; Anthony Delitto
Journal:  Am J Gastroenterol       Date:  2016-08-30       Impact factor: 10.864

7.  Exercise and physical activity in cirrhosis: opportunities or perils.

Authors:  Annette Bellar; Nicole Welch; Srinivasan Dasarathy
Journal:  J Appl Physiol (1985)       Date:  2020-04-02

Review 8.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 9.  Cause and management of muscle wasting in chronic liver disease.

Authors:  Srinivasan Dasarathy
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

Review 10.  Nutrition and exercise in the management of liver cirrhosis.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.